Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Hedge Funds Recommend Amgen Inc. AMGN as the Best Pharma Stock to Buy

March 20, 2025
According to recent reports, hedge funds are strongly recommending Amgen Inc. (AMGN) as the best pharma stock to buy. With its strong financial performance, innovative products, and solid growth prospects, Amgen has caught the attention of several hedge funds. The company's robust pipeline, which includes potential breakthrough treatments for various diseases, further adds to its appeal. This news has caught the attention of investors, who are now considering buying Amgen stock. If you are interested in making a profit from this trend, it is recommended to seek professional advice from experts at Stocks Prognosis, who can provide accurate predictions on the future movements of Amgen Inc. AMGN shares.

Find out how the AMGEN INC. rate is expected to change

Get Forecast for AMGN

Investor opinions & comments:

I've been a long-term investor in Amgen and I'm pleased to see that hedge funds are recognizing its potential. I have confidence in the company's ability to deliver
— from OliviaJackson at 03-23-2025 14:50
I've been looking to invest in the pharmaceutical sector and Amgen seems like a promising choice. I'll definitely consider buying their stock
— from BrittanyClark at 03-23-2025 10:43
The solid pipeline of potential breakthrough treatments is a strong indicator of Amgen's future success. I'm excited about the opportunities this presents for investors
— from GraceStewart at 03-23-2025 08:11
Amgen's strong financial performance and innovative products make it an appealing investment choice. I believe in their potential for growth in the pharmaceutical industry
— from WealthyWhitney at 03-23-2025 06:52
I'm glad to hear that Amgen's pipeline includes potential breakthrough treatments. This could be a game-changer for the company and its investors
— from FinanceFlo at 03-23-2025 02:26
I'm not sure if this recommendation is just a result of a promotional campaign. I'll wait for more independent analysis before making any investment decisions
— from CarterPatterson at 03-21-2025 12:20
Hedge funds have been known to manipulate stock prices for their own gain. I'll approach this recommendation with caution and do thorough research before making a move
— from WealthyWendy at 03-21-2025 05:01
I've done my research and Amgen seems to be a well-positioned company in the pharma industry. I'm optimistic about the potential returns it could bring to my investment portfolio
— from BudgetBrittany at 03-20-2025 20:15
Hedge funds may have their own agenda and their recommendations might not always align with the best interest of individual investors. I'll consult with my financial advisor before considering Amgen
— from BenjaminParker at 03-20-2025 15:59
I trust the recommendations of hedge funds, so I'll be keeping an eye on Amgen and do my own research before making a decision
— from TraderTobias at 03-20-2025 13:48
If you want to leave a comment, then you need Login or Register





Other news for AMGN

AMGNApril 22, 2025Amgen Inc. AMGN: Among the Innovative Healthcare Stocks to Watch in 2025  ~2 min.

Amgen Inc., a leading biotechnology company, is currently one of the most promising stocks in the healthcare sector....

AMGNMarch 19, 2025Amgen Inc. AMGN: Cutting-Edge Biotech Company Dominates Stock Market  ~2 min.

Amgen Inc. (AMGN), renowned for its groundbreaking innovations in biotechnology, continues to make headlines as a leading player in the stock market....

AMGNMarch 17, 2025Amgen Inc. Continues to Impress Hedge Funds with Strong Performance  ~2 min.

Amgen Inc. (NASDAQ:AMGN) has emerged as the top choice for hedge funds looking to invest in the pharmaceutical sector....

AMGNMarch 16, 2025Amgen Inc. AMGN: Discover Why it's Among the Top Pharma Stocks to Buy  ~2 min.

Amgen Inc., a leading biotechnology company, has been gaining attention in the investment community due to its outstanding performance in the pharmaceutical sector....

AMGNMarch 7, 2025AMGEN INC. Hits Price Target Forecast with 19.78% Profit, as Predicted by QuantWave  ~2 min.

AMGEN INC. (AMGN) recently achieved the price target forecast set by QuantWave, resulting in a profit of 19.78% for investors who followed the prediction....



Related news

GSKFebruary 25, 2025GlaxoSmithKline (GSK) Enhances Pipeline Plans with Breakthrough Treatment - Stocks Prognosis  ~3 min.

GlaxoSmithKline, commonly known as GSK, a leading global pharmaceutical company, has recently made significant progress in its pipeline plans by developing a breakthrough treatment for a life-threatening disease. The company's innovative research and development efforts have paid off, leading to the creation of a promising drug that could potentially revolutionize the healthcare industry. GSK's br...

AZNJanuary 2, 2025AstraZeneca PLC Announces Breakthrough in Cancer Treatment Research  ~2 min.

AstraZeneca PLC, a leading global pharmaceutical company, has reported a significant breakthrough in its cancer treatment research....

PFENovember 11, 2024Pfizer Inc. Announces Groundbreaking Breakthrough in COVID-19 Treatment  ~2 min.

Pfizer Inc., the renowned pharmaceutical company, has made a groundbreaking discovery in the fight against COVID-19....

AZNJanuary 1, 2025New breakthrough in medical research announced by AstraZeneca PLC AZN  ~2 min.

Leading pharmaceutical company AstraZeneca PLC AZN has made a groundbreaking discovery in the field of medical research....

BMYDecember 19, 2024Bristol Myers Squibb Awards $25M Milestone Payment for Breakthrough ALS Treatment Target Discovery - Stock Prognosis Recommendation  ~1 min.

Bristol-Myers Squibb Company (BMY) recently awarded a milestone payment of $25 million for the discovery of a breakthrough treatment target for ALS (Amyotrophic lateral sclerosis), also known as Lou Gehrig's disease. The significant achievement was made possible through a collaboration with insitro, a leading precision medicine company. The selection of the first novel genetic target marks a major...